US6815161B1ExpiredUtility

Detection of Mycoplasma in patients with chronic fatigue syndrome and related disorders

43
Assignee: IMMUNOSCIENCES LAB INCPriority: Apr 1, 1999Filed: Apr 1, 1999Granted: Nov 9, 2004
Est. expiryApr 1, 2019(expired)· nominal 20-yr term from priority
Inventors:Aristo Vojdani
C12Q 2600/16C12Q 1/6895C12Q 1/6883
43
PatentIndex Score
5
Cited by
27
References
27
Claims

Abstract

A method for determining an increased likelihood of the presence of chronic fatigue syndrome (CFS), fibromyalgia (FMS), or rheumatoid arthritis (RA) in an individual, comprising isolating blood cells from the individual and determining the presence of one or more Mycoplasma species present in the blood cells, wherein the presence of one or more Mycoplasma species indicates an increased likelihood of the presence of CFS, FMS, RA or GWS.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
       1. A method for determining an increased likelihood of the presence of chronic fatigue syndrome (CFS) or fibromyalgia (FMS) in an individual, comprising the steps of: 
       isolating peripheral blood mononuclear cells (PBMC) from said individual; and  
       detecting the presence of at least one  mycoplasma  species, wherein said at least one species comprises  M. hominis,  wherein the presence of at least one of said species indicates an increased likelihood of the presence of CFS or FMS.  
     
     
       2. The method of  claim 1 , wherein the  mycoplasma  species additionally comprises a species selected from the group consisting of  M. fermentans  and  M. penetrans.    
     
     
       3. The method of  claim 1 , wherein said detecting step comprises a polynucleotide amplification reaction. 
     
     
       4. The method of  claim 3 , wherein said detecting step comprises multiplex PCR. 
     
     
       5. The method of  claim 1 , wherein said detecting step comprises Southern hybridization or dot blot hybridization. 
     
     
       6. The method of  claim 3 , wherein said amplification reaction comprises use of two or more oligonucleotide primers selected from the group consisting of the sequences shown in SEQ ID NOS: 3-8, wherein said two or more primers include primers having the sequences shown in SEQ ID NOS: 5 and 6 so as to amplify a 170 base pair region of  M. hominis  DNA. 
     
     
       7. The method of  claim 6 , wherein the the amplification reaction comprises use of the primers having sequences shown in SEQ ID NOS: 3 and 4 so as to amplify a 206 base pair region of  M. fermentans  DNA. 
     
     
       8. The method of  claim 6 , wherein the the amplification reaction comprises use of the primers having sequences shown in SEQ ID NOS: 7 and 8 so as to amplify a 407 base pair region of  M. penetrans  DNA. 
     
     
       9. The method of  claim 1 , wherein the detecting step comprises detecting two or more of said  mycoplasma  species. 
     
     
       10. The method of  claim 9 , wherein the two or more species comprise  M. hominis  and a species selected from the group consisting of  M. fermentans  and  M. penetrans.    
     
     
       11. The method of  claim 10 , wherein  M. fermentans, M. hominis  and  M. penetrans  are all detected. 
     
     
       12. The method of  claim 9 , wherein the two or more species are simultaneously detected. 
     
     
       13. The method of  claim 11 , wherein  M. fermentans, M. hominis  and  M. penetrans  are detected simultaneously. 
     
     
       14. A method for determining an increased likelihood of the presence of rheumatoid arthritis (RA) in an individual, comprising the steps of: 
       isolating peripheral blood mononuclear cells (PBMC) from said individual; and  
       detecting the presence of at least one  mycoplasma  species in said PBMC, wherein the presence of at least one of said species indicates an increased likelihood of the presence of RA.  
     
     
       15. The method of  claim 14 , wherein the species detected is selected from the group consisting of  M. fermentans, M. hominis  and  M. penetrans.    
     
     
       16. The method of  claim 14 , wherein said detecting step comprises a polynucleotide amplification reaction. 
     
     
       17. The method of  claim 16 , wherein said detecting step comprises multiplex PCR. 
     
     
       18. The method of  claim 14 , wherein said detecting step comprises Southern hybridization or dot blot hybridization. 
     
     
       19. The method of  claim 16 , wherein said amplification reaction comprises use of two or more oligonucleotide primers selected from the group consisting of the sequences shown in SEQ ID NOS: 3-8. 
     
     
       20. The method of  claim 19 , wherein the amplification reaction comprises use of the primers having sequences shown in SEQ ID NOS: 3 and 4 so as to amplify a 206 base pair region of  M. fermentans  DNA. 
     
     
       21. The method of  claim 19 , wherein the amplification reaction comprises use of the primers having sequences shown in SEQ ID NOS: 5 and 6 so as to amplify a 170 base pair region of  M. hominis  DNA. 
     
     
       22. The method of  claim 19 , wherein the amplification reaction comprises use of the primers having sequences shown in SEQ ID NOS: 7 and 8 so as to amplify a 407 base pair region of  M. penetrans  DNA. 
     
     
       23. The method of  claim 14 , wherein the detecting step comprises detecting two or more  mycoplasma  species. 
     
     
       24. The method of  claim 23 , wherein the two or more species are selected from the group consisting of  M. fermentans, M. hominis  and  M. penetrans.    
     
     
       25. The method of  claim 24 , wherein  M. fermentans, M. hominis  and  M. penetrans  are all detected. 
     
     
       26. The method of  claim 23 , wherein the two or more species are simultaneously detected. 
     
     
       27. The method of  claim 25 , wherein  M. fermentans, M. hominis  and  M. penetrans  are detected simultaneously.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.